Gilead, Biogen Down On Patent Rulings; Ionis, Merck, Forward Rise

Big biotechs Gilead Sciences (GILD) and Biogen (BIIB) were both trading down Wednesday morning after receiving unfavorable patent news.

Late TuesdayIonis Pharmaceuticals (IONS) said that it and its big pharma partner Merck (MRK) had won a case alleging that Gilead’s hepatitis C virus (HCV) drug sofosbuvir, which is sold individually as Sovaldi and as an ingredient in Harvoni, infringed on patents that Ionis and Merck had obtained from earlier research.

“We used our expertise in a 1998...

What feeling does this article give you?

#hashtags to follow:

Gilead Sciences [+]    GILD [+]    Biogen [+]    BIIB [+]    Late Tuesday [+]    Ionis Pharmaceuticals [+]    IONS [+]    Merck [+]    MRK [+]    Gilead [+]    HCV [+]    Sovaldi [+]    Harvoni [+]    Ionis and Merck [+]   

More #news: